← Back

enGene Holdings Inc. Common Stock

ENGNUSD
1.73-80.5%1Y · USD

enGene Therapeutics Inc., through its subsidiary enGene, Inc., is a clinical-stage biotechnology company based in Montreal, Canada. It develops genetic medicines for patients with bladder cancer. Its lead product candidate, detalimogene voraplasmid, is a monotherapy for non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026.

Price · split & dividend adjusted
News & notes moving ENGN
ENGN▼

enGene Holdings Q3 GAAP EPS Misses Estimates

enGene Holdings reported a third-quarter GAAP loss of $0.47 per share, missing analyst expectations by $0.04. As of July 31, 2026, the company held $266.3 million in cash, cash equivalents, and marketable securities, providing significant operational flexibility.
ENGN · Capital · Negative Q3 GAAP EPS of -$0.47 missed analyst estimates by $0.04.
Read original ↗
Seeking Alpha·33dRead more →